Therakos LLC

Therakos LLC manufactures the THERAKOS® CELLEX® Photopheresis System, an FDA-approved extracorporeal photopheresis (ECP) device for the palliative treatment of skin manifestations of cutaneous T-cell lymphoma (CTCL) unresponsive to other therapies. The system performs ultraviolet-A (UVA) irradiation of leukocyte-enriched blood in the presence of 8-methoxypsoralen (8-MOP), with co-administered pharmaceutical UVADEX® (methoxsalen) sterile solution. The company provides a complete therapeutic platform including the photopheresis system hardware, consumables, operator training through the Therakos Institute, and comprehensive customer support services branded as Therakos Total Care. The system is designed for use in clinical settings where standard medical emergency equipment and volume management capability are available. Following acquisition by CVC, certain operations continue under transition services agreement with Mallinckrodt Pharmaceuticals. Therakos markets primarily to hematology-oncology centers, dermatology departments, and specialized treatment centers managing CTCL patients. The company maintains dedicated business manager support and professional education programs for treating physicians and clinical staff. Product indications and contraindications are clearly defined with specific patient selection criteria and comprehensive safety protocols documented in the operator's manual and UVADEX prescribing information.